

The Protective Role of Commensal Bacteria in Intestine

Anran Niu

School of Chemistry and Molecular Bioscience, University of Queensland, St Lucia QLD 4072, Australia.

Corresponding Author*

Anran Niu, School of Chemistry and Molecular Bioscience, University of Queensland, St Lucia QLD 4072 Australia, E-mail: anran.niu@uq.net.au

Copyright: © 2021 Niu A. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Received date: December 11, 2020; Accepted date: December 28, 2020; Published date: February 28, 2021

Abstract

Commensal bacteria have co-evolved with the host species to dominant the microbial community in the gastrointestinal tract. Intestinal symbiotic bacteria affect various aspects of host healthy status. Germ-free animals are usually associated with weaker immunity and higher susceptibility to disease. This review briefly summarizes the roles played by commensal bacteria in protecting the host and the mechanisms involved from the host point of view. Overall, these mechanisms can be divided into three actions including maintaining physical intestinal barrier function, stimulating production of host defence components, and modulating cellular immunity.

Keywords: Anti-microbial peptide • Bacteria • Cellular immunity • Immunoglobulin's • Intestinal barrier

Introduction

The relationship between the host and commensal bacteria is the product of long-term and complex coevolution [1]. In this largely symbiotic relationship, the host provides a habitat for different microbial species that in turn benefit host health through various host- microbe interactions. The human gastrointestinal tract is an extensive interface exposed to the environment and colonized by trillions of microbes dominated by bacteria, with more than 1000 bacterial species [2]. Gastrointestinal symbiotics not only serve as a foreign organ by contributing to host nutrition and energy homeostasis, but also assist in the development and maintenance of the host immune system [3]. Perturbation in microbiota has been reported in chronic gastrointestinal, neurologic, and metabolic diseases such as Inflammatory Bowel Disease (IBD), type 2 diabetes, atherosclerosis, allergy, and even colon cancer [4]. Protection of host cells achieved by commensal microbes is an extremely complex process involving many different factors and mechanism, such as competing for nutrients [5], producing microbes-derived anti-microbial properties [6], and regulating the host immune system [7]. This review will focus on the role of commensal bacteria in regulating host immune system, summarising the various mechanisms involved from the host perspective. These mechanisms can be divided into three actions including maintaining physical intestinal barrier function, stimulating production of host defence components, and modulating cellular immunity. Commensal bacteria help maintain host physical barriers through stimulating the production of mucins and tight junctions to protect the host from pathogenic and viral intrusion. Commensal bacteria also stimulate production of host defence molecules like anti-microbial peptides and immunoglobulins that can kill invading pathogens, and finally commensal bacteria can modulate cellular immunity by regulating the number, differentiation, migration, and downstream signaling of immune cells




Figure 1. The protective function of intestinal commensal bacteria. MC: Mast cell; DC: Dendritic cells; Treg cells: Regulatory T cells; Th cells: Helper T cells; NETs: Neutrophil Extracellular Traps; ROS: Reactive Oxygen Species. .

Maintain function of physical intestinal barrier

Mucus and Mucin: The mucus layer in the intestine serves as the first line of defence against the environment and prevents the intestinal epithelial layer from direct contact with microorganisms, thereby protecting the intestinal epithelial barrier from pathogenic attack and helping to maintain intestinal homeostasis [8]. Goblet cells secrete hydrated mucin molecules that are crucial components of mucus formation. However, mucins are also substrates for microbes and can be degraded by bacteria such as *Helicobacter pylori* and *Akkermansia muciniphila* [10]. Previous studies highlight how one action by commensal bacteria to protect the host involves stimulating mucin synthesis that helps restore mucin levels degraded by pathogenic bacteria. For example, an in vitro study by Mack et al [11], found that *Lactobacillus plantarum* increased Muc2 and Muc3 mRNA levels in HT29 human goblet-like cells and suppressed adherence and invasion of pathogenic *Escherichia coli* (E. coli) O157:H7. These findings are in agreement with a more recent study by Mack et al [11] where *Lactobacillus* strains adhered to HT29 cells, induced Muc3 gene transcription and translation, increased extracellular Muc3 mucin production, and blocked adherence of enteropathogenic E. coli E2348/69. Another study investigating a mixture of probiotic bacterial agents (VSL#3), also reported an increase in Muc2, Muc3, and Muc5AC mucin gene expression and secretion in HT29 cells [12].

The exact mechanisms involved in protection of the host physical intestinal barrier by commensal bacteria remain unknown, however the mechanisms appear to depend on the ability of commensal bacteria to adhere to the mucus layer, facilitate interactions with host cells, and stimulate mucin production [13]. Probiotic bacteria may also compete for binding sites with pathogenic microbes essentially limiting the binding of invading pathogens to the mucus layer. However, it has also been proposed that mucin secretion induced by commensal bacteria is not dependent on adhesion but facilitated by molecules secreted by bacteria. For instance, findings from an in vitro study showed that VSL#3 bacterial conditioned media stimulated secretion of mucin more than the VSL#3 bacteria [14]. In another study, *Lactobacillus acidophilus* A4 cell extracts significantly increased Muc2 expression in HT29 cells [15]. Ulcerative colitis patients present with decreased thickness of the mucus layer, particularly in the active inflammation sites [16]. Hence, understanding the mechanisms involved in protection of intestinal

barrier integrity by commensal bacteria will aid in the development of clinical treatment to restore and improve gut barrier function in patients.

Tight junction: Tight Junctions (TJ) modulate intestinal barrier integrity and are essential for intercellular adhesion. TJ mainly comprised of transmembrane proteins, such as occludin and claudin, adaptor proteins, such as Zonula Occludens 1 (ZO-1), regulatory proteins, and transcriptional and post-transcriptional regulators [17]. These TJ proteins work together to maintain intestinal barrier integrity, prevent entry of pathogens, regulate passive transport of molecules, and limit free exchange of apical and basolateral components across membranes [18]. Paracellular permeability and Transepithelial Electrical Resistance (TER) are indicators of intestinal integrity and barrier function. Many factors, including cytokines, chemicals, pathogens, and stress, can compromise the intestinal barrier by decreasing TER and increasing paracellular permeability that can allow pathogen invasion and infection. Changes in TJ composition and structure are usually associated with IBD and can impact TJ function. For example, increased gut permeability is characteristic of inflammatory bowel diseases and is present in patients with Crohn's disease before clinical relapse [19]. Loss of ZO-1 and increased intestinal permeability was reported in mice treated with Dextran Sulfate Sodium (DSS) prior to exhibiting intestinal inflammation.

In animal studies involving a DSS induced mouse model of colitis, reduced levels of TJ protein, enhanced epithelial injury, and higher mortality were observed in germ-free mice compared to control mice with normal microbiota [20]. Interestingly, transplanting human faecal commensal microbiota into germ-free mice restored intestinal barrier structure and function to normal levels, and also reduced susceptibility to intestinal injury [21]. In more precise studies, treatment with commensal bacteria have been investigated to help maintain intestinal barrier integrity by regulating production of TJ proteins [22,23]. Several *in vitro* studies have also confirmed *in vivo* findings, for example *Lactobacillus casei* modulated ZO-1 expression, restored reduced TER, and increased epithelial permeability induced by cytokines in a Caco-2 cell model [15]. Another study by Resta-Lenert and Barrett [24] demonstrated that both live *Streptococcus thermophilus* and *Lactobacillus acidophilus* induced occluding and ZO-1 expression, increased TER, and decreased permeability of human intestinal epithelial cell lines, thus protecting intestinal epithelial cells from the infection of enteroinvasive *E. coli*, compared with controls containing culture media and inactive bacteria.

Stimulate defence components production

Antimicrobial peptides: Defensins and cathelicidins are two major families of antimicrobial peptides secreted by innate leukocytes, like macrophages and epithelial cells, or stored in intracellular compartments, like neutrophil granules and Paneth cells [25]. Defensins and cathelicidin are cationic peptides that play important roles in the host defence system by directly killing invading pathogens, or by modulating innate and adaptive immune responses, including chemokine production and pro-inflammatory cytokine production [25]. Deficiencies in antimicrobial peptides, like defensins, contribute to IBD development and are associated with a higher risk of pathogen invasion [26,27]. Activation of microorganism-sense Pattern Recognised Receptors (PRRs) like Toll-Like Receptors (TLRs), can trigger synthesis of antimicrobial peptides through signalling pathways such as Nuclear Factor Kappa B (NF- κ B) and Mitogen-Activated Protein Kinases (MAPKs) [28]. In a Caco-2 cell model, *E. coli* [29] (EcN) and *Lactobacillus plantarum* stimulated secretion of human β -Defensin 2 (hBD-2) and increased expression of TLRs [30,31]. These host responses to bacteria have also been investigated clinically. For instance, a clinical trial showed that faecal levels of hBD-2 protein significantly increased in healthy participants administered Symbioflor 2 (a mixture of several commensal *E. coli* strains) twice daily for three weeks, compared to the control group who received placebo treatments and did not

exhibit any changes in hBD-2 protein levels [32].

Immunoglobulin: Immunoglobulin A (IgA) is the dominant non-inflammatory antibody in mucosal surfaces and can be distinguished as serum IgA and Secretory IgA (SIgA) [33]. IgA translocates to the surface of epithelial cells where it binds to a Polymeric Ig Receptor (pIgR) before being secreted as SIgA. The pIgR receptor is expressed on the basolateral surface of epithelial cells and functions as an antibody transporter [34].

Release of SIgA protects the intestinal epithelial barrier from microbial pathogens and antigens through various mechanisms. For example, SIgA prevents pathogens and antigens from adhering to intestinal epithelial cells by forming hydrophilic shells repelled by epithelial-glycocalyx. SIgA can also bind receptors expressed on immune cells to activate antimicrobial activity, anti- or pro-inflammatory responses, or immune exclusion. Furthermore, SIgA plays a crucial role in preventing invasion and infection, and maintaining intestinal microbiota homeostasis by directly binding and neutralizing virulence factors [35]. IgA was shown to present lower level in germ-free animals but were rapidly restored by microbial colonization [36]. Mice pre-treated with *Bifidobacterium* also showed four-fold higher levels of rotavirus-specific IgA in serum, compared with control mice 28 and 42 days after rotavirus inoculation [37]. The importance of commensal bacteria and IgA was also highlighted by another study where *Lactobacillus casei* increased anti-Shiga toxin IgA antibodies in a rabbit model of Shiga toxin-producing *E. coli* infection and reduced morbidity [38].

Immunoglobulin G (IgG), another abundant and important immunoglobulin in mucosal immunity, helps to protect the mucosa from pathogens and maintains mucosal homeostasis [39]. The impact of bacteria on IgG has been explored less than IgA, however a study by Ansaldo reported upregulation of B cell-generated IgG through CD4+ T cells in mice in response to *Akkermansia muciniphila* [40].

Regulate immune cells and cell-mediated immunity

Mast cells: Mast Cells (MCs) play an important role in allergic reactions, and also participate in inflammatory processes, tissue repair, and angiogenesis [41]. Mast cells are very early and rapid responders to viruses, toxins, and other pathogens by detecting and recognising detrimental signals through cell-surface PRRs [42]. Evolution has equipped MCs with various responses to resistant invading pathogens including secretion of bioactive mediators, such as protease, cytokines, and chemokines, formation of MC-extracellular traps, and phagocytosis [43,44]. In a study by Kunii et al, intestinal commensal bacteria promoted migration of MCs from the blood to the intestine [45]. In another study, reduced levels of mucosal MCs, and protease II produced by MCs, were measured in intestinal lymph from rats treated with antibiotics [46]. However, even though activation of MCs inhibit pathogens, it also contributes to intestinal barrier dysfunction [47]. Notably, *Lactobacillus casei* [48] reversed MC activation and inhibited other MC mediators induced by enterotoxigenic *E. coli* K88, thus maintaining integrity of the intestinal barrier [48].

Macrophages: Macrophages (MPs) act as scavengers and maintain intestinal homeostasis through phagocytosis of microbes and apoptotic cells. In addition to phagocytosis, MPs also secrete cytokines and chemokines to regulate downstream signalling and play a role in initiating adaptive immunity, like presenting antigens to T cells. Macrophages can be characterized into two types, Macrophages 1 (M1) and 2 (M2). The first type, M1, are involved in inflammation and express pro-inflammatory cytokines, like Tumour Necrosis Factor- α (TNF- α) and Interleukin-6 (IL-6), in response to pathogens. The second type, M2, produce anti-inflammatory cytokines, like Interleukin-10 (IL-10), and promote tissue repair and growth [49]. Activation of MPs is essential for defence against invading pathogens and for removal of pathogens. The role of commensal bacteria in modulating MPs has been well studied. For

example, decreased numbers of MPs were observed in the colon of germ-free mice, while pre-treatment of MPs with *Lactobacillus* increased phagocytosis and bactericidal activity against pathogens such as *S. aureus*, *S. typhimurium*, and *E. coli*. Bacteria can also modulate production of cytokines by MPs, as evidenced by a study where a single strain of *Clostridium butyricum* stimulated production of IL-10 by intestinal MPs in inflamed mucosa alleviating experimental colitis in mice [50].

Neutrophils: Neutrophils are produced in Bone Marrow (BM) and are the most abundant leukocytes in blood. These immune cells are attracted to various chemical signals and are among the first responders to migrate towards inflammatory sites. Similar to MCs, neutrophils protect the host through phagocytosis and release of cytokines, however neutrophils also release granular proteins, Reactive Oxygen Species (ROS), and Neutrophil Extracellular Traps (NETs) [51]. Neutrophils isolated from antibiotic-treated and germ-free mice displayed a significantly reduced capacity to kill pathogens, compared to neutrophils from control mice [52]. The activation of neutrophils is essential for killing invading pathogens, however excessive immune response by neutrophils can promote tissue damage. The commensal bacteria *Bifidobacterium longum* 51A has been shown to alleviate the inflammatory response and decrease neutrophil recruitment and accumulation in an experimental gout murine model [53]. Another study proposed that probiotic *Lactobacillus rhamnosus* GG inhibited formation of NETs induced by chemicals and *Staphylococcus aureus*, consequently reducing ROS production and preventing destruction of surrounding cells [54]. Different neutrophil responses to probiotic bacteria have been reported by several studies [55-57]. The precise pathway and response to bacteria, however, still need more investigations. Subsequently, further studies are needed to better understand the mechanisms and signalling pathways involved in neutrophil responses to bacteria.

Dendritic cells: Dendritic Cells (DCs), also known as antigen presenting cells, are in constant communication with other cells by direct cell-cell contact mediated through cell-surface proteins, or via distant interactions involving cytokines. Immature DCs exhibit high endocytic activity but limited capacity to activate T cells when compared to mature DCs. However, once activated by contact with an antigen, immature DCs mature and migrate to lymph nodes where they present antigens to T cells and antibody-producing B cells. Importantly, antigen presentation induces the adaptive immune response, thus mature DCs serve as messengers between innate and adaptive immunity. A study showed that treatment with *Bifidobacterium animalis* ssp. *lactis* 5764 efficiently induced maturation of DCs from bone marrow that was accompanied by an improvement in acute intestinal inflammation [58]. Plasmacytoid DCs (pDCs) are a subset of DCs and play an important role in viral resistance. The administration of I strain plasma showed the capacity to improve the decrease in pDC activity caused by heat stress in a mice model [59]. Notably, commensal bacteria sometimes do not only have an impact on DCs themselves but influence other downstream innate immune cells. Natural Killer (NK) cells are a type of cytotoxic lymphocytes. In a study involving germ-free mice, NK cells exhibit reduced antiviral activity associated with compromised antiviral immunity due to failure of DCs to release cytokines, such as IL-15 required for NK cell priming [60].

T cells: T cell responses are initiated by Antigen-Presenting Cells (APCs) such as macrophages and dendritic cells. Once activated, T cells develop into memory T cells and several distinct types of effector T cells including Helper T (Th) cells, Regulatory T (Treg) cells, and cytotoxic T cells. In addition to the ability of upregulating memory T cells by oral administration of *Bacillus subtilis* [61], several studies have shown that commensal bacteria are also involved in regulating immunity mediated by Treg cells. Treg cells play a crucial role in immune tolerance and prompting termination

of the immune response to avoid autoimmunity and excessive damage to the body that can be caused by this physiological state [62]. Treatment with *Bifidobacterium infantis* increased the number of Treg cells, and alleviated intestinal damage caused by *Salmonella* infection [63]. Moreover, treatment with *Bacillus fragilis* induced Treg cells to secrete IL-10, thus protecting the host from damage caused by *Helicobacter hepaticus* infection [64]. In contrast to Treg cells which suppress immune response, Th cells differentiate into several subtypes with different roles to stimulate immune responses by other immune cells. However, the excessive activation of Th can contribute to autoimmunity and inflammation [65]. Hence, the balance between Th cells and Treg cells are crucial in maintain immune homeostasis [66]. Certain *Lactobacillus* species, for example, *Lactobacillus acidophilus* [67] and *Lactobacillus casei* [68] balance Treg and Th17 cell populations and stimulate expression of cytokines leading to reduced intestinal inflammation and 1,2-Dimethylhydrazine (DMH)-induced colorectal cancer. Another study showed that *Bifidobacterium infantis* effectively attenuated chemotherapy-induced intestinal mucositis by decreasing Th1 and Th17 response, and by increasing CD4+ CD25+ Foxp3+ Tregs response [69-71].

Conclusion

This review briefly summarised the protective roles commensal bacteria play in regulating and maintaining the host immune system. Interactions between bacteria and the host not only enhance host defence system, but also regulate cellular immune response. Understanding how commensal bacteria benefit the host can provide insights into treatments targeting various diseases. The roles commensal bacteria play in host protection have been extensively studied; however the precise mechanisms, mediators, and pathways involved are still unclear. Short chain fatty acids, the main products of bacterial fermentation of undigested dietary fibre in the intestine, have been a major focus in this field of research reported by many studies as protective mediators. In addition, bacterial cell wall components, like peptidoglycan and lipopolysaccharide, have also been identified by host cell-surface PRRs in the induction of immune responses. Moreover, both Gram-negative and Gram-positive bacteria can produce membrane vesicles that contain many bioactive components that modulate the host immune system. The precise roles of these mediators and the mechanism involved require further investigation.

Acknowledgements

No funding supports this work. The author appreciates people who provided help for this work.

References:

1. Ley RE., et al. "Worlds within worlds: Evolution of the vertebrate gut microbiota". *Nature Reviews Microbiology*. 2008; pp: 776-788.
2. Eckburg PB., et al. "Microbiology: Diversity of the human intestinal microbial flora. *Science*". 2005; 308(5728): 1635-1638
3. Cummings JH., & MacFarlane GT. "Role of intestinal bacteria in nutrient metabolism". *Clinical Nutrition*. 1997; 16(1): 3-11
4. Holmes E., et al. "Understanding the role of gut microbiome-host metabolic signal disruption in health and disease". *Trends in Microbiology*. 2011; 19(7): 349-359.
5. Maltby R., et al. "Nutritional Basis for Colonization Resistance by Human Commensal *Escherichia coli* Strains HS and Nissle 1917 against *E. coli* O157:H7 in the Mouse Intestine". *Plos One* 2013; 08(1).
6. Winston JA., & Theriot CM. "Impact of microbial derived secondary bile acids on colonization resistance against

- Clostridium difficile in the gastrointestinal tract" *Anaerobe*. 2016; 41: pp 44-45.
7. Littman DR., & Pamer EG. "Role of the commensal microbiota in normal and pathogenic host immune responses". *Cell Host and Microbe*. 2011; 10(4): 311-323.
 8. Hansson GC. "Role of mucus layers in gut infection and inflammation". *Current Opinion in Microbiology*. 2012; 15(1): 57-62
 9. Windle HJ., et al. "The thioredoxin system of *Helicobacter pylori*". *Journal of Biological Chemistry*. 2000; 275(7): 5081-5089.
 10. van Passel MWJ., et al. "The genome of *Akkermansia muciniphila*, a dedicated intestinal mucin degrader, and its use in exploring intestinal metagenomes". *Plos One* 2011; 6(3): 1-3.
 11. Mack David R., et al. "Probiotics inhibit enteropathogenic *E. coli* adherence in vitro by inducing intestinal mucin gene expression". *American Journal of Physiology - Gastrointestinal and Liver Physiology*. 1999; 276(4): G941-G950.
 12. Otte JM., & Podolsky DK. "Functional modulation of enterocytes by gram- positive and gram-negative microorganisms". *American Journal of Physiology - Gastrointestinal and Liver Physiology*. 2004; 286(4): G613-G636.
 13. van Tassel ML., & Miller MJ. "Lactobacillus adhesion to mucus". *Nutrients*. 2011; 3(5): 613-636.
 14. Caballero-Franco C., et al. "The VSL#3 probiotic formula induces mucin gene expression and secretion in colonic epithelial cells. *American Journal of Physiology*" - Gastrointestinal and Liver Physiology. 2007; 292(1): G315-G322
 15. Eun CS., et al. "Lactobacillus casei prevents impaired barrier function in intestinal epithelial cells". *APMIS*. 2011; 119(1): 49-56.
 16. Strugala V., et al. "Thickness and continuity of the adherent colonic mucus barrier in active and quiescent ulcerative colitis and Crohn's disease". *International Journal of Clinical Practice*. 2008; 65(5): 762-769.
 17. Lodemann U., "Effects of Probiotics on Intestinal Transport and Epithelial Barrier Function". *Bioactive Foods in Promoting Health*. 2010; pp 303-333.
 18. Zihni C., et al. "Tight junctions: From simple barriers to multifunctional molecular gates". *Nature Reviews Molecular Cell Biology*. 2016; 17: 564-580.
 19. Arnott IDR., et al. "Abnormal intestinal permeability predicts relapse in inactive Crohn disease". *Scandinavian Journal of Gastroenterology*. 2000; 35(11).
 20. Hernández-Chirlaque C., et al. "Germ-free and antibiotic-treated mice are highly susceptible to epithelial injury in DSS colitis". *Journal of Crohn's and Colitis*. 2016; 10(11): 1324-1335.
 21. Hayes CL., et al. "Commensal microbiota induces colonic barrier structure and functions that contribute to homeostasis". *Scientific Reports*. 2018
 22. Ait-Belgnaoui A., et al. "Lactobacillus farciminis treatment suppresses stress induced visceral hypersensitivity: A possible action through interaction with epithelial cell cytoskeleton contraction". *Gut*. 2006; 55(8).
 23. Resta-Lenert S., & Barrett KE. "Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive *Escherichia coli* (EIEC)". *Gut*. 2003; 52(7).
 24. Resta-Lenert S., & Barrett KE. "Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive *Escherichia coli* (EIEC)". *Gut*. 2003; 52(7).
 25. Bowdish DME., et al. "Immunomodulatory properties of defensins and cathelicidins". *Current Topics in Microbiology and Immunology*. 2006; 22(66).
 26. Wehkamp J., et al. "Reduced Paneth cell α - defensins in ileal Crohn's disease". *Proceedings of the National Academy of Sciences of the United States of America*. 2005; 102(50): 18129-18134.
 27. Wilson CL., et al. "Regulation of intestinal α - defensin activation by the metalloproteinase matrilysin in innate host defense". *Science*. 1999; 286(5437): 113-117.
 28. Froy, O. "Regulation of mammalian defensin expression by Toll-like receptor- dependent and independent signalling pathways". *Cellular Microbiology*. 2005; 7(10): 1387-1397.
 29. Maltby R., et al. "Nutritional Basis for Colonization Resistance by Human Commensal *Escherichia coli* Strains HS and Nissle 1917 against *E. coli* O157:H7 in the Mouse Intestine". *Plos One*. 2013; 8(1).
 30. Paolillo R., et al. "Immunomodulatory effects of *Lactobacillus plantarum* on human colon cancer cells". *International Immunopharmacology*. 2009; 9(11): 1265-1271
 31. Schlee M., et al. "Induction of human β -defensin 2 by the probiotic *Escherichia coli* Nissle 1917 is mediated through flagellin". *Infection and Immunity*. 2007; 75(5): 2399-2407
 32. Möndel M., et al, "Probiotic *E. coli* treatment mediates antimicrobial human β -defensin synthesis and fecal excretion in humans". *Mucosal Immunology*. 2009; 2(2): 166-172
 33. MacPherson AJ., et al. "The immune geography of IgA induction and function". *Mucosal Immunology*. 2008; 1(1): 11-22.
 34. Mostov KE., & Deitcher DL. "Polymeric immunoglobulin receptor expressed in MDCK cells transcytoses IgA". *Cell*. 1986; 46(4): 613-621.
 35. Mantis NJ., et al. "Secretory IgA's complex roles in immunity and mucosal homeostasis in the gut". *Mucosal Immunology*. 2011; 4(4): 603-611.
 36. Hapfelmeier S., et al. "Reversible microbial colonization of germ-free mice reveals the dynamics of IgA immune responses". *Science*. 2010; 328(5986): 1705-1709.
 37. Qiao H., et al. "Immune responses in rhesus rotavirus-challenged Balb/c mice treated with bifidobacteria and prebiotic supplements". *Pediatric Research*. 2002; 51(6): 750-755.
 38. Ogawa M., et al. "Protective effect of *Lactobacillus casei* strain Shirota on Shiga toxin-producing *Escherichia coli* O157:H7 infection in infant rabbits". *Infection and Immunity*. 2001; 69(2): 1101
 39. Chen K., et al. "Rethinking mucosal antibody responses: IgM, IgG and IgD join IgA". *Nature Reviews Immunology*. 2020; 20(6): 427-441.
 40. Ansaldo E., et al. "*Akkermansia muciniphila* induces intestinal adaptive immune responses during homeostasis". *Science*. 2019; 364(6446): 1179-1184.
 41. da Silva EZM., et al. "Mast Cell Function: A New Vision of an Old Cell". *Journal of Histochemistry and Cytochemistry*. 2014; 62(10): 698-738
 42. Agier J., et al. "An overview of mast cell pattern recognition receptors". *Inflammation Research*. 2018; 67: 737-746
 43. Möllerherm H., et al. "Antimicrobial activity of mast cells: Role and relevance of extracellular DNA traps". *Frontiers in Immunology*. 2016; 7.

44. Saccheri P., et al. "Mast cells, an evolutionary approach". *Italian Journal of Anatomy and Embryology*. 2019; 124(30): 271-287.
45. Kunii J., et al. "Commensal bacteria promote migration of mast cells into the intestine". *Immunobiology*. 2011; 216(6): 692-697
46. Hayashi A., et al. "A single strain of *Clostridium butyricum* induces intestinal IL-10-producing macrophages to suppress acute experimental colitis in mice". *Cell Host and Microbe*. 2013; 13(6): 711-722.
47. Pastwińska J., et al. "Mast cells as the strength of the inflammatory process". *Polish Journal of Pathology*. 2017; 68(3): 187-196.
48. Xu C., et al. "Lactobacillus casei ATCC 393 alleviates Enterotoxigenic *Escherichia coli* K88-induced intestinal barrier dysfunction via TLRs/mast cells pathway". *Life Sciences*. 2020; 244.
49. Bashir S., et al. "Macrophage polarization: the link between inflammation and related diseases". *Inflammation Research*. 2016; 65: 1-11
50. Hayashi A., et al. "A single strain of *Clostridium butyricum* induces intestinal IL-10-producing macrophages to suppress acute experimental colitis in mice". *Cell Host and Microbe*. 2013; 13(6): 711-722.
51. Hickey MJ., & Kubes P. "Intravascular immunity: The host-pathogen encounter in blood vessels". *Nature Reviews Immunology*. 2009; 9: 364-375.
52. Clarke TB., et al. "Recognition of peptidoglycan from the microbiota by Nod1 enhances systemic innate immunity". *Nature Medicine*. 2010; 16: 228-231.
53. Vieira AT., et al. "Oral treatment with *Bifidobacterium longum* 51A reduced inflammation in a murine experimental model of gout". *Beneficial Microbes*. 2015; 6 (6): 799-806.
54. Vong L., et al. "Probiotic *Lactobacillus rhamnosus* Inhibits the Formation of Neutrophil Extracellular Traps". *The Journal of Immunology*. 2014; 192 (4): 1870-1877.
55. Felix KM., et al. "Gut microbiota contributes to resistance against Pneumococcal Pneumonia in immunodeficient Rag1 Mice". *Frontiers in Cellular and Infection Microbiology*. 2018.
56. Lajqi T., et al. "The Role of Microbiota in Neutrophil Regulation and Adaptation in Newborns". *Frontiers in Immunology*. 2020.
57. Llewellyn A., & Foey A. "Probiotic modulation of innate cell pathogen sensing and signaling events". *Nutrients*. 2017; 9 (10): 1156
58. Hrdý J., et al. "Plasmacytoid dendritic cell dysfunction caused by heat stress is improved by administration of *Lactococcus lactis* strain plasma in mice". *Bioscience, Biotechnology and Biochemistry*. 2019; 83 (11): 2140–2143.
59. Ganai SC., et al. "Priming of Natural Killer Cells by Nonmucosal Mononuclear Phagocytes Requires Instructive Signals from Commensal Microbiota". *Immunity*. 2012; 37 (1): 171-186.
60. Hayes CL., et al. "Commensal microbiota induces colonic barrier structure and functions that contribute to homeostasis". *Scientific Reports*. 2018.
61. Xu B., et al. "The ratio of circulating follicular T helper cell to follicular T regulatory cell is correlated with disease activity in systemic lupus erythematosus". *Clinical Immunology*. 2017; 183: 46-53
62. O'Mahony C., et al. "Commensal-induced regulatory T cells mediate protection against pathogen-stimulated NF- κ B activation". *PLoS Pathogens*. 2008.
63. Mazmanian SK., et al. "A microbial symbiosis factor prevents intestinal inflammatory disease". *Nature*. 2008; pp: 620-625.
64. Kunkl M., et al. "Helper Cells: The Modulators of Inflammation in Multiple Sclerosis". *Cells*. 2020; 9 (2): 482.
65. Lee GR., "The balance of th17 versus treg cells in autoimmunity". *International Journal of Molecular Sciences*. 2018; 19 (3): 730.
66. Park JS., et al. "Lactobacillus acidophilus Improves Intestinal Inflammation in an Acute Colitis Mouse Model by Regulation of Th17 and Treg Cell Balance and Fibrosis Development". *Journal of Medicinal Food*. 2018; 21 (3).
67. Lenoir M., et al. "Lactobacillus casei BL23 regulates Treg and Th17 T-cell populations and reduces DMH-associated colorectal cancer". *Journal of Gastroenterology*. 2016; pp: 862-873.
68. Mi H., et al. "Bifidobacterium Infantis Ameliorates Chemotherapy-Induced Intestinal Mucositis Via Regulating T Cell Immunity in Colorectal Cancer Rats". *Cellular Physiology and Biochemistry*. 2017; 42: 2330–234.
69. Kazemi Sefat NA., et al. "Sodium Butyrate as a Histone Deacetylase Inhibitor Affects Toll-Like Receptor 4 Expression in Colorectal Cancer Cell Lines". *Immunological Investigations*. 2019; 48(7): 759–769.
70. Lemme-Dumit JM., et al. "Probiotic bacteria cell walls stimulate the activity of the intestinal epithelial cells an macrophage functionality". *Beneficial Microbes*. 2018; 9 (1): 153-164.
71. Caruana JC., & Walper SA. "Bacterial Membrane Vesicles as Mediators of Microbe – Microbe and Microbe – Host Community Interactions". *Frontiers in Microbiology*. 2020.